NCT07898488Not yet recruiting
Glycemic Control in Leukemia Patients
Prognostic Significance of Combined Red Cell Distribution Width and Glycated Hemoglobin / Hemoglobin Glycation Index in Leukemia: A Prospective Study.
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
Glycemic control in leukemia patients
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 54 (estimated)
- First submitted
- 21 Oct 2026
- Start date
- 12 Dec 2026
- Primary completion date
- 12 Dec 2028
- Lead sponsor
- Assiut University
- Diseases
- Childhood cancers
- NCT number
- NCT07898488
What you commit to
- Study type: Observational
- Planned participants: 54
- From 12 Dec 2026 to the primary completion date, 12 Dec 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Recent blood transfusion within the preceding 3 months before baseline glycemic assessment.
- Active severe co-existing acute infection or sepsis independent of leukemia diagnosis.
- Known pre-existing active secondary malignancy. Pregnancy or lactation. History of severe hemoglobinopathies (e.g., sickle cell anemia, thalassemia major) that significantly alter erythrocyte lifespan independent of disease.
- Incomplete clinical data or loss to follow-up.
Who the study is looking for
- Age ≥ 18 years. Newly diagnosed, histologically/cytologically confirmed adult leukemia patients (AML, ALL, CML, or CLL) before starting definitive induction therapy.
- Provision of written informed consent.
Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.